Metastatic Tumor

20 registered clinical trials studyying Metastatic Tumor — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors NCT07404332	Mohammed Milhem	Phase 1
Recruiting	A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957	NiKang Therapeutics, Inc.	Phase 1
Not Yet Recruiting	A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors NCT06383507	Zhejiang University	Phase 1
Terminated	A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921	NiKang Therapeutics, Inc.	Phase 1
Recruiting	Definitive Radiation for High-Risk Spine Metastases NCT06165419	Stony Brook University	Phase 2
Recruiting	A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases NCT05717166	David Palma	Phase 3
Active Not Recruiting	A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer NCT05678010	Memorial Sloan Kettering Cancer Center	Phase 1
Completed	Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patien NCT05665348	Federation Francophone de Cancerologie Digestive	Phase 2 / Phase 3
Active Not Recruiting	A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors NCT05731271	Suzhou Transcenta Therapeutics Co., Ltd.	Phase 1 / Phase 2
Unknown	A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T NCT05468190	Chongqing Precision Biotech Co., Ltd	Phase 1
Recruiting	A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors NCT05518253	Weijia Fang, MD	Phase 1
Completed	A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors NCT05396300	Weijia Fang, MD	Phase 1
Unknown	A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors NCT05420545	Chongqing Precision Biotech Co., Ltd	Phase 1
Unknown	Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer NCT05420519	Chongqing Precision Biotech Co., Ltd	Phase 1
Terminated	Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Met NCT05099549	NKGen Biotech, Inc.	Phase 1 / Phase 2
Unknown	Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors NCT05415475	Chongqing Precision Biotech Co., Ltd	Phase 1
Completed	A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumor NCT03238027	Syndax Pharmaceuticals	Phase 1
Completed	Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid NCT02977156	Centre Leon Berard	Phase 1
Recruiting	Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Ra NCT06473259	Santa Chiara Hospital	—
Completed	A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread NCT01648764	Eli Lilly and Company	Phase 1